NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.25+1.14 (+2.77%)
At close: 4:00PM EST
People also watch
ALKSLGNDPGNXNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close41.11
Open41.17
Bid40.00 x 100
Ask54.97 x 1000
Day's Range41.09 - 43.57
52 Week Range31.25 - 55.15
Volume1,336,495
Avg. Volume1,060,288
Market Cap3.67B
Beta0.63
PE Ratio (TTM)-29.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017
    Capital Cube6 days ago

    Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Neurocrine Biosciences, Inc. a score of 29. Our analysis is based on comparing Neurocrine Biosciences, Inc. with the following peers – Repligen Corporation, Repros Therapeutics Inc., Paratek Pharmaceuticals Inc, Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company, AbbVie, Inc., CASI Pharmaceuticals Inc, ANI Pharmaceuticals, Inc. and ... Read more (Read more...)

  • Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017
    Capital Cube7 days ago

    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Zacks Small Cap Research10 days ago

    NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA

    On January 5, 2017, Neurocrine Biosciences, Inc. (NBIX) announced that the Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting that was originally scheduled for Feb. 16, 2017 after further review of the INGREZZA™ New Drug Application (NDA). The FDA informed the company that the Priority Review of the NDA for INGREZZA™ for the treatment of tardive dyskinesia (TD) was continuing as planned with the previously announced Prescription Drug User Fee Act (PDUFA) date of April 11, 2017. During the conference call to discuss the situation, management indicated that they have had nothing but positive interactions with the FDA up to and during review of the NDA and that they were not aware of any issues with the review of the NDA.